fda glp-1 warning news september 2025 Fmr. Commissioner weighs in on Medicare's involvement in prices GLP-1 RA prescription trends: January

J Gastroenterol 2017

By striving to reconcile the disparity between its considerable neuroprotective potential and recent clinical challenges, we can enhance our understanding of the potential role of semaglutide and other GLP-1 receptor agonists in combating cognitive decline

Since then, the number one question patients ask is whether their insurance will cover it and for the millions of Americans on Blue Cross Blue Shield plans, the answer is frustratingly complicated

Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushings syndrome

Liraglutide was approved by the FDA for marketing in the United States in 2010 and officially launched in China in 2011